Apellis (APLS) Form 3: Officer Leslie Meltzer Reports No Holdings

Apellis Pharmaceuticals filed an initial Form 3 reporting that Leslie Meltzer, the company's Chief Research and Development Officer and an officer/director, submitted a statement of beneficial ownership tied to an event dated 08/26/2025.

Rhea-AI Filing Summary

Apellis Pharmaceuticals filed an initial Form 3 reporting that Leslie Meltzer, the company's Chief Research and Development Officer and an officer/director, submitted a statement of beneficial ownership tied to an event dated 08/26/2025. The filing discloses that no securities are beneficially owned by the reporting person. The form was signed on behalf of Ms. Meltzer by an attorney-in-fact, David Watson, with a signature date of 09/02/2025. The filing includes the reporting person's Waltham, MA business address but contains no holdings, derivative positions, or other ownership details.

Positive

• None.

Negative

• No securities are beneficially owned by the reporting person as of the 08/26/2025 event date

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Apellis (APLS) Form 3 filed for Leslie Meltzer report?

The Form 3 reports that Leslie Meltzer, Chief Research and Development Officer, does not beneficially own any securities of Apellis as of the 08/26/2025 event date.

When was the Form 3 for Leslie Meltzer signed and by whom?

The Form 3 was signed by attorney-in-fact David Watson with a signature date of 09/02/2025.

Does the filing list any derivative securities or stock options for Ms. Meltzer?

No. The filing's tables state explicitly: No securities are beneficially owned, and no derivative securities or options are listed.

What title and address are shown for the reporting person on the Form 3?

The filing lists Leslie Meltzer as Chief Research and Development Officer and gives a business address at 100 Fifth Avenue, 3rd Floor, Waltham, MA 02451.

Is this Form 3 an individual filing or a joint filing?

The form indicates it was filed by one reporting person (individual filing).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/02/2025 - 10:12 AM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

MELTZER LESLIE

(Last) (First) (Middle)

C/O APELLIS PHARMACEUTICALS, INC.

100 FIFTH AVENUE, 3RD FLOOR

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/26/2025

3. Issuer Name and Ticker or Trading Symbol
Apellis Pharmaceuticals, Inc. [ APLS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Research and Development

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ David Watson, attorney-in-fact for Leslie Meltzer	09/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.